Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Joint Bioscinces has 1 pending office action in Biotechnology & Pharmaceuticals. The matter involves 1 distinct examiner and 1 distinct art unit. CORNELIUS, CLAIRE ADRIENNE is the busiest examiner, with 1 pending office action, placing the recorded work in one examiner and art-unit assignment.
Counsel can center the prosecution plan on CORNELIUS, CLAIRE ADRIENNE and the identified art unit. Claim amendments, technical explanations, and supporting evidence can be prepared for the biotechnology or pharmaceutical issues raised in this office action. The single recorded assignment permits a direct response strategy and avoids the need to reconcile differing examiner approaches.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORNELIUS, CLAIRE ADRIENNE | 1 | 71.4% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18493787 | ONCOLYTIC VIRUS COMBINED WITH CAR T CELLS FOR ANTI-TUMOR THERAPY | CORNELIUS, CLAIRE ADRIENNE | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18493787 | ONCOLYTIC VIRUS COMBINED WITH CAR T CELLS FOR ANTI-TUMOR THERAPY | CORNELIUS, CLAIRE ADRIENNE | 1672 | §102§103§112 | Final Rejection | 4d overdue | Pending | Oct 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJoint Bioscinces has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Claire Adrienne Cornelius has the most, with 1 of Joint Bioscinces's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.